Plain-English translation of NCT07046494 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called to see if it can help treat manic episodes in people with bipolar I disorder. Researchers want to understand how well the medication works and whether it is safe. Half of the participants will receive , and half will receive a placebo (an inactive pill that looks identical) to compare the results.
Currently, people experiencing manic episodes have limited treatment options, and researchers are working to develop new medications that might work better or have fewer side effects. This study will help determine whether this medication could become a valuable option for people struggling with acute mania.
You would stay in a hospital or inpatient research facility for 3 weeks. During that time, you would receive either the new medication or a placebo daily, and researchers would monitor your symptoms, mood, and overall health through regular assessments. You would not know which treatment you are receiving, and neither would the study staff—this helps ensure fair results.
AI-generated summary from trial data · Aug 28, 2026 · Not medical advice
United States